HETERODIMERE VON GLUTAMINSÄURE

European patent · EP3699162 · Deleted

Register entry

Publication number
EP3699162
Application number
EP19214298
Kind
European patent with effect for Switzerland and Liechtenstein
Status
Deleted
Specification
Granted
Filed
Nov 7, 2007
Published
Aug 26, 2020
Granted
Jun 29, 2022
Deleted
Feb 25, 2026
Reason
Revoked in opposition
IPC classes
C07B 59/00 (2006.01)
A61K 51/00 (2006.01)
Priority
US 857490 P 08.11.2006
US 878678 P 05.01.2007
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Feb 25, 2026

    Status of protective title

    Status of protective title
    Active → Cancelled
    Cancellation date
    25.02.2026
    Cause for cancellation
    Opposition

    Published in Swissreg on 25.02.2026

  2. Dec 1, 2025

    Change

    Published in Swissreg on 01.12.2025

  3. Dec 1, 2024

    Change

    Published in Swissreg on 01.12.2024

  4. Dec 1, 2023

    Change

    Published in Swissreg on 01.12.2023

  5. Jan 18, 2023

    Change

    Published in Swissreg on 18.01.2023

  6. Dec 1, 2022

    Change

    Published in Swissreg on 01.12.2022

  7. Sep 14, 2022

    Agent entered

    Representative
    Novagraaf International SA, Chemin de l'Echo 3, 1213 Onex

    Published in Swissreg on 14.09.2022

  8. Jun 29, 2022

    Granted

    Published in Swissreg on 29.06.2022

Parties

Holder

Molecular Insight Pharmaceuticals, Inc.

One World Trade Center 47th Floor, Suite J, New York, NY 10007, US

Agent

Novagraaf International SA

Chemin de l'Echo 3, 1213 Onex

Inventor

MARESCA, Kevin P.

Tewksbury, MA Massachusetts 01876, US

ZIMMERMAN, Craig N.

Topsfield, MA Massachusetts 01983, US

BABICH, John W.

New York, NY New York 10028, US

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.